Unfortunately, even if the diagnosis and treatment facilities have increased, the number of breast cancer patients has been rising throughout the years. The latest data published showed that approximately 2.3 million women were diagnosed with breast cancer in 2020, with a record 685,000 deaths. Genetic studies, including genome-wide association (GWAS), whole-genome sequencing (WGS), whole-exome sequencing (WES), or simply genetic association studies, have been used to understand the genetic basis of breast cancer. Variation in the toxicity and responsiveness to a single dose of therapy may occur in cancer patients, contributing to the unpredictability of clinical results. Besides the possible role of clinical considerations in influencing medication effects, genetic variations in drug metabolism are anticipated to impact treatment results significantly. Pharmacogenetics, the study of how genetic variation contributes to these interindividual variances, may enable more personalized treatment and improved prediction of pharmacodynamic outcomes, such as host toxicity and treatment success.
The aim of this Research Topic is to identify the clear and exact mechanism of breast cancer and suggest personalized treatment regimens to tailor each patient's treatment regimen based on an accurate estimate of the patient's risk of cancer recurrence or progression. Nowadays, pharmacogenomics-based tactics represent novel approaches for minimizing toxicity while optimizing medication effectiveness. Additionally, genomic profiling of malignant tumors may pave the way for creating tailored medicines that may be included in successful medication regimens. It is possible to treat breast cancer using a variety of readily accessible drugs. For a more favorable prognosis, treatment options such as systemic chemotherapy, endocrine therapy, or HER2-targeted therapy are recommended based on tumor characteristics and the status of its hormone receptors (HRs), such as the estrogen receptor (ER), the progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2).
The Topic Editors welcome a wide variety of Research Topics including, but not limited to, original research, reviews, systemic reviews, case reports, hypotheses and theories, clinical trials, opinions, or commentaries that will cover the following:
• Genetic, epigenetic, transcriptomic studies, GWAS, Whole genome sequencing studies and case-control association studies.
• Response and toxicity of systemic chemotherapy connected with biomarkers.
• Effectiveness of anthracyclines, cyclophosphamide, methotrexate, 5 flourouracil, platinum compounds, taxanes, antiestrogens, capecitabine, gemcitabine and aromatase Inhibitors in breast cancer treatment.
• Pharmacogenomic Biomarkers.
• Pharmacogenomic biomarker connected breast cancer drug resistance.
The authors are also encouraged to submit relevant articles that may shed light on revealing the underlying mechanism of breast cancer, as well as the studies that may help to develop novel strategies for the treatment of breast cancer.
Unfortunately, even if the diagnosis and treatment facilities have increased, the number of breast cancer patients has been rising throughout the years. The latest data published showed that approximately 2.3 million women were diagnosed with breast cancer in 2020, with a record 685,000 deaths. Genetic studies, including genome-wide association (GWAS), whole-genome sequencing (WGS), whole-exome sequencing (WES), or simply genetic association studies, have been used to understand the genetic basis of breast cancer. Variation in the toxicity and responsiveness to a single dose of therapy may occur in cancer patients, contributing to the unpredictability of clinical results. Besides the possible role of clinical considerations in influencing medication effects, genetic variations in drug metabolism are anticipated to impact treatment results significantly. Pharmacogenetics, the study of how genetic variation contributes to these interindividual variances, may enable more personalized treatment and improved prediction of pharmacodynamic outcomes, such as host toxicity and treatment success.
The aim of this Research Topic is to identify the clear and exact mechanism of breast cancer and suggest personalized treatment regimens to tailor each patient's treatment regimen based on an accurate estimate of the patient's risk of cancer recurrence or progression. Nowadays, pharmacogenomics-based tactics represent novel approaches for minimizing toxicity while optimizing medication effectiveness. Additionally, genomic profiling of malignant tumors may pave the way for creating tailored medicines that may be included in successful medication regimens. It is possible to treat breast cancer using a variety of readily accessible drugs. For a more favorable prognosis, treatment options such as systemic chemotherapy, endocrine therapy, or HER2-targeted therapy are recommended based on tumor characteristics and the status of its hormone receptors (HRs), such as the estrogen receptor (ER), the progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2).
The Topic Editors welcome a wide variety of Research Topics including, but not limited to, original research, reviews, systemic reviews, case reports, hypotheses and theories, clinical trials, opinions, or commentaries that will cover the following:
• Genetic, epigenetic, transcriptomic studies, GWAS, Whole genome sequencing studies and case-control association studies.
• Response and toxicity of systemic chemotherapy connected with biomarkers.
• Effectiveness of anthracyclines, cyclophosphamide, methotrexate, 5 flourouracil, platinum compounds, taxanes, antiestrogens, capecitabine, gemcitabine and aromatase Inhibitors in breast cancer treatment.
• Pharmacogenomic Biomarkers.
• Pharmacogenomic biomarker connected breast cancer drug resistance.
The authors are also encouraged to submit relevant articles that may shed light on revealing the underlying mechanism of breast cancer, as well as the studies that may help to develop novel strategies for the treatment of breast cancer.